Novartis, CRISPR Tx, and Miltenyi Report Clinical Updates from Their New Assets in Lymphomas; ASH 2022 Analysis 5
Here is a brief preview of this blast: ASH 2022 Analysis 5: Novartis, CRISPR Tx, and Miltenyi presented clinical updates from their cell therapies in lymphoma. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered below: